ANKARA
Turkey has signed a contract to buy 50 million doses of the COVID-19 vaccine from China’s Sinovac Biotech, Effectively being Minister Fahrettin Koca has talked about.
Turkey has a deal for 50 million doses of China’s Sinovac vaccine that may be delivered in December, January, and February, in accordance with the minister.
“If all goes well, we plan to start vaccinating at-risk groups gradually, starting with our healthcare personnel,” he talked about, together with that folk may be vaccinated freed from cost.
As a minimum 10 million doses of the Chinese language language vaccine may be delivered in December, nevertheless the aim is to acquire some 20 million doses and one different 20 million doses are scheduled for January and a minimum of 10 million doses may be acquired in February, Koca detailed.
Speaking in Ankara after the Effectively being Ministry’s Science Board meeting on Nov. 25, Koca reiterated that Turkey may also be in talks with completely different vaccine builders, along with Russia.
“The important thing here for us to start using vaccines which are known to be effective and reliable … I think the vaccination calendar could start on Dec. 11,” he talked about.
The minister earlier this month unveiled that Ankara hoped to buy doses of Pfizer and BioNTech’s vaccine.
If the Pfizer and BioNTech vaccine obtains its license, Turkey may get 1,000,000 doses of the vaccine by the tip of the 12 months. We’re in talks to repeatedly go as a lot as 25 million inside a 12 months starting from January, Koca talked about in the mean time.
On the press meeting on Nov. 25, the minister reminded that Turkey is ending up analysis to develop its private vaccines.
Works are underway for 16 potential vaccines and a type of candidate jabs has already been administered to 44 volunteers, Koca well-known.
“No serious side effects have been reported. The phase three trials of this potential injection will take place in April the latest and the locally-developed vaccine could be launched for use that month,” he talked about.